Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL813870 | 0.89 | — | — | |
| SCHEMBL813836 | 0.83 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL813923 | 0.77 | GABRA1 (0.37) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL814440 | 0.77 | GABRA1 (0.37) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL813993 | 0.77 | GABRA1 (0.37) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL814262 | 0.77 | FABP4 (0.40) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL813286 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL813778 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL814442 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL815656 | 0.77 | GABRA1 (0.34) | GABRA1GABRB2FABP3FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | disclosed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | disclosed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | GABRA1 4178/4885GABRB2 3205/4885FABP3 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.